Heart Failure and Obesity

Emily Morris, Oliver J Rider

Read time: 19m 30s
AHA 25: HFpEF as an Adipose Tissue Disorder

Milton Packer

Watch time: 5m 43s
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology

Chim C Lang, Bianca Rocca, Samira Bell, et al

Watch time: 14m 14s
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows

Radcliffe CVRM

Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s
ESC HF 25: The PRAISE-HFrEF Study

Varun Sundaram

Watch time: 4m 10s
THT 2025: The SUMMIT Trial

Barry Borlaug

Watch time: 6m 31s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status

Mikhail Kosiborod

Watch time: 12m 9s
HFSA 24: The HuMAIN-HFpEF Trial

Ambarish Pandey

Watch time: 4m 5s
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie

Harriette Van Spall, Mark Petrie

Watch time: 15m 26s
EP 105: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Listen time: 1h 5m 20s

Emily Morris, Oliver J Rider

Read time: 19m 30s
ACC.24: The STEP HFpEF DM Trial

Mikhail Kosiborod

Watch time: 6m 41s
AHA 25: HFpEF as an Adipose Tissue Disorder

Milton Packer

Watch time: 5m 43s
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Harriette Van Spall, Mikhail Kosiborod

Watch time: 13m 24s
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie

Harriette Van Spall, Mark Petrie

Watch time: 15m 26s
HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF

Harriette Van Spall, Mikhail Kosiborod

Watch time: 12m 4s
HFSA 24: The HuMAIN-HFpEF Trial

Ambarish Pandey

Watch time: 4m 5s
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology

Chim C Lang, Bianca Rocca, Samira Bell, et al

Watch time: 14m 14s
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status

Mikhail Kosiborod

Watch time: 12m 9s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s

Media

AHA 25: HFpEF as an Adipose Tissue Disorder

Milton Packer

Watch time: 5m 43s
HFSA 25: Sex-Specific Outcomes of Tirzepatide in Obesity-Related HFpEF

Barry Borlaug

Watch time: 7m 15s
Obesity in Focus: Implications for Heart Failure, Kidney Disease, and Pharmacology

Chim C Lang, Bianca Rocca, Samira Bell, et al

Watch time: 14m 14s
Managing Obesity in HF: 2025 ACC Scientific Statement

Michelle Kittleson

Watch time: 8m 5s
ESC HF 25: The PRAISE-HFrEF Study

Varun Sundaram

Watch time: 4m 10s
THT 2025: The SUMMIT Trial

Barry Borlaug

Watch time: 6m 31s
AHA 24 Late-Breaking Discussion: The SUMMIT Trial

Harriette Van Spall, Milton Packer

Watch time: 17m 22s
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status

Mikhail Kosiborod

Watch time: 12m 9s
HFSA 24: The HuMAIN-HFpEF Trial

Ambarish Pandey

Watch time: 4m 5s
HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF

Harriette Van Spall, Mikhail Kosiborod

Watch time: 12m 4s
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie

Harriette Van Spall, Mark Petrie

Watch time: 15m 26s
ACC.24: The STEP HFpEF DM Trial

Mikhail Kosiborod

Watch time: 6m 41s

Articles

Targeting Obesity for Heart Failure

Emily Morris

,

Oliver J Rider

,

Published:

23 December 2025

Citation:

European Cardiology Review 2025;20:e38.

DOI:

https://doi.org/10.15420/ecr.2025.37
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Downloads: Downloads 64
  • Read time: 19m 30s